Renuvion APR System When Used as an Adjunct Procedure In Gynecomastia Surgery
NCT ID: NCT05093049
Last Updated: 2024-02-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2021-10-22
2022-08-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Mentor Becker Expander/Breast Implant in Subjects Who Are Undergoing Primary Breast Reconstruction
NCT00750685
Following the Use of Gel Prosethetics in Breast Reconstruction
NCT00585884
A Pilot Study to Evaluate the BodyLogic TM System (Mentor) in Augmentation Mammaplasty
NCT00684749
Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction
NCT05130580
Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue
NCT02614885
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At baseline, the grade of gynecomastia was recorded by side, male chest measurements will be taken, and pre-surgery photographs taken in the frontal, lateral, and oblique views.
The gynecomastia surgery and Renuvion APR System use were as per investigator's standard clinical practice. During the procedure, fat transfer and treatment of the lateral chest and/or axilla was not allowed. The Renuvion APR System was used on one side only. The Renuvion treated side was randomized and the patient was blinded as to which side of the chest received Renuvion. Procedure data and adverse events were captured. Endermology was not allowed post-procedure. Post-procedure compression was used for 2-3 weeks with a standard compression vest for all subjects.
Follow-up images, grade of gynecomastia, and male chest measurements were taken at D30/D90/D180.
All images were assessed for correct identification of Renuvion-treated side by blinded Independent Photographic Reviewers (IPR) following the D180 visit.
Following study participation, the subject was offered an optional balancing treatment to the side not previously treated with Renuvion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gynecomastia Surgery Followed by Renuvion
Patients receiving gynecomastia correction surgery followed by Renuvion treatment were randomly assigned to the left or the right side of the chest in a split-body randomized design. The gynecomastia surgery and Renuvion APR System use will be as per investigator's standard clinical practice.
Renuvion APR System
The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
Gynecomastia Correction Surgery
Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
Gynecomastia Surgery Only
Patients receiving gynecomastia correction surgery followed by Renuvion treatment were randomly assigned to the left or the right side of the chest in a split-body randomized design. The gynecomastia surgery will be as per investigator's standard clinical practice.
Gynecomastia Correction Surgery
Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Renuvion APR System
The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
Gynecomastia Correction Surgery
Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ASA Physical Status Classification System Class I and Class II subjects.
3. Clinical diagnosis of primary or secondary Gynecomastia.
4. Gynecomastia Rohrich Grade IIA or higher.
5. Symmetrical gynecomastia Rohrich grades.
6. Symmetrical chest measurements (no more than 3% variance between sides).
7. Scheduled for Gynecomastia surgery.
8. Willing to have Renuvion APR System as an adjunct procedure on one side understanding that an optional balancing procedure may be provided post-study exit.
9. Understands and accepts the obligation not to undergo any other procedures or treatments in the areas to be treated during study participation.
10. Absence of physical conditions unacceptable to the investigator.
11. Willing and able to comply with protocol requirements, including study-required images/photos, assessments/measurements, and returning for follow-up visits.
12. Willing to release rights for the use of study photos, including in publication.
13. Able to read, understand, sign, and date the informed consent.
Exclusion Criteria
2. Subjects presenting with ASA Physical Status Classification System Classes III or higher.
3. Gynecomastia Rohrich Grade I.
4. Non-symmetrical gynecomastia Rohrich grades.
5. Non-symmetrical chest measurements (more than 3% variance between sides).
6. Previous treatment or surgery in the breast area.
7. Active systemic or local skin disease that may alter wound healing.
8. Significant or uncontrolled medical condition that in the opinion of the investigator participation in the study may compromise the patient's health.
9. History of autoimmune disease (excluding Hashimoto's thyroiditis).
10. Known susceptibility to keloid formation or hypertrophic scarring.
11. Cancerous or pre-cancerous lesions in the area to be treated.
12. Possesses a surgically implanted electronic device (i.e. pacemaker).
13. Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years.
14. Use of endermology post-procedure for the duration of the study.
15. Participation in any other investigational study within 30 days prior to consent and throughout study participation.
16. Subject who, in the opinion of the investigator, is not an appropriate candidate for the study.
18 Years
75 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Apyx Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul G Ruff, MD
Role: PRINCIPAL_INVESTIGATOR
West End Plastic Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West End Plastic Surgery
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APX-21-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.